IL6 and Castleman disease: Siltuximab (EUSA Pharma, Hempstead, UK and BeiGene Ltd., Beijing, China) is a chimeric IgG1 targeting IL-6, indicated in patients with multicentric Castleman’s disease and evaluated in Phase 3 in COVID-19 (NCT04330638).